title: Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?
abstract: Patients with mild cognitive impairment (MCI) were assessed, and a metabolic profile associated with conversion to AD at 18-month follow-up was sought. As compared with nonconverters (n = 10), converters (n = 7) had lower fluorodeoxyglucose uptake in the right temporoparietal cortex (p = 0.02, corrected for cluster size), without individual overlap. Awaiting replication in an independent sample, these findings suggest that among patients with MCI, fluorodeoxyglucose PET may accurately identify rapid converters.
authors.affiliation: INSERM EO 218, University of Caen, Cyceron PET Center, France.
authors.forename: G
authors.initials: G
authors.lastname: Chételat
authors.forename: B
authors.initials: B
authors.lastname: Desgranges
authors.forename: V
authors.initials: V
authors.lastname: de la Sayette
authors.forename: F
authors.initials: F
authors.lastname: Viader
authors.forename: F
authors.initials: F
authors.lastname: Eustache
authors.forename: J-C
authors.initials: JC
authors.lastname: Baron
mesh_terms: D000544:Alzheimer Disease / Q000000981:diagnostic imaging* / Q000453:epidemiology; D001921:Brain / Q000000981:diagnostic imaging; D018450:Disease Progression; D005260:Female; D019788:Fluorodeoxyglucose F18; D006179:Gyrus Cinguli / Q000000981:diagnostic imaging; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000000981:diagnostic imaging; D008875:Middle Aged; D009483:Neuropsychological Tests; D010296:Parietal Lobe / Q000000981:diagnostic imaging; D011446:Prospective Studies; D019275:Radiopharmaceuticals; D012307:Risk Factors; D016037:Single-Blind Method; D013702:Temporal Lobe / Q000000981:diagnostic imaging; D014055:Tomography, Emission-Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18